drugset / Trial / NCT01226732
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors. This combination treatment has potential applicability in tumor types where capecitabine or fluorouracil is a treatment option, including colorectal and breast cancer.
Timeline
- Start
- 2010-11
- Primary completion
- 2013-07
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AUY922 | Small molecule | 22 mg/m2 | Intravenous |
| Subject | AUY922 | Small molecule | 28 mg/m2 | Intravenous |
| Subject | AUY922 | Small molecule | 40 mg/m2 | Intravenous |
| Subject | AUY922 | Small molecule | 55 mg/m2 | Intravenous |
| Subject | AUY922 | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |